REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 30th, 2024 • Pasithea Therapeutics Corp. • Pharmaceutical preparations
Contract Type FiledSeptember 30th, 2024 Company IndustryThe undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:
SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT Pasithea Therapeutics Corp.Security Agreement • September 30th, 2024 • Pasithea Therapeutics Corp. • Pharmaceutical preparations
Contract Type FiledSeptember 30th, 2024 Company IndustryTHIS [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ______________1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Pasithea Therapeutics Corp., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 30th, 2024 • Pasithea Therapeutics Corp. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 30th, 2024 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of September 26, 2024, between Pasithea Therapeutics Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Pasithea Therapeutics Corp.Placement Agent Common Stock Agreement • September 30th, 2024 • Pasithea Therapeutics Corp. • Pharmaceutical preparations
Contract Type FiledSeptember 30th, 2024 Company IndustryTHIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on October 1, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Pasithea Therapeutics Corp., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain engagement letter, dated as of September 6, 2024, as amended on September 26, 2024, by and between the Company and H.C. Wainwright & Co., LLC.
PRE-FUNDED COMMON STOCK PURCHASE WARRANT Pasithea Therapeutics Corp.Pre-Funded Common Stock Agreement • September 30th, 2024 • Pasithea Therapeutics Corp. • Pharmaceutical preparations
Contract Type FiledSeptember 30th, 2024 Company IndustryTHIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Pasithea Therapeutics Corp., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).